Novartis’s defeat in its India patent battle Monday raises a number of questions, not the least of which is whether the Swiss drug maker — and other drug giants — now could see other countries rise up and challenge its patents. Aaron Kesselheim, HMS assistant professor of medicine at Brigham and Women’s Hospital, recently authored an article on the extension of drug patents.
